Walleye Capital LLC Editas Medicine, Inc. Put Options Transaction History

Walleye Capital LLC

12 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$3.39 - $5.96 $141,363 - $248,532	41,700 Added 695.0%	47,700 $162,000
Q2 2024 Aug 14, 2024	BUY	$4.67 - $7.28 $26,619 - $41,496	5,700 Added 1900.0%	6,000 $28,000
Q1 2024 May 15, 2024	BUY	$7.03 - $11.07 $2,109 - $3,321	300 New	300 $2,000
Q1 2023 May 15, 2023	SELL	$7.03 - $11.53 $2,109 - $3,459	-300 Reduced 0.8%	37,200 $269,000
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $239,616 - $380,448	28,800 Added 331.03%	37,500 $332,000
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $105,792 - $168,954	8,700 New	8,700 $106,000
Q2 2020 Aug 14, 2020	SELL	$18.5 - $34.34 $111,000 - $206,040	-6,000 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$14.88 - $32.78 $255,936 - $563,816	-17,200 Reduced 74.14%	6,000 $119,000
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $9,745 - $16,315	500 Added 2.2%	23,200 $687,000
Q3 2019 Nov 14, 2019	BUY	$22.49 - $26.81 $204,659 - $243,971	9,100 Added 66.91%	22,700 $516,000
Q2 2019 Aug 14, 2019	BUY	$20.48 - $27.76 $145,408 - $197,096	7,100 Added 109.23%	13,600 $336,000
Q1 2019 May 15, 2019	BUY	$19.43 - $26.41 $126,295 - $171,665	6,500 New	6,500 $159,000

246

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $94.2M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.